A recently published study in JAMA sought to determine if there is a link between acetaminophen use during pregnancy and children’s risk of developing autism, ADHD, or intellectual disabilities.
A newly published study has found that there is no link between acetaminophen use during pregnancy and the risk of children developing a neurodevelopmental disorder, despite a previous consensus statement cautioning its use during pregnancy.1
Acetaminophen is one of the most commonly used drugs for managing pain and fever in pregnancy, with both the FDA and European Medicines Agency deeming the drug to pose minimal risk when used during pregnancy.2,3
However, a 2021 consensus statement supported by 91 scientists, clinicians, and public health professionals, cautioned the use of paracetamol (N-acetyl-p-aminophenol [APAP] or acetaminophen) during pregnancy, citing “increasing experimental and epidemiological research suggests that prenatal exposure to APAP might alter fetal development, which could increase the risks of some neurodevelopmental, reproductive, and urogenital disorders.”4
A recently published JAMA study sought to investigate the use of acetaminophen during pregnancy and the risk of autism, attention-deficit/hyperactivity disorder (ADHD), and intellectual disability in approximately 2.5 million children in Sweden from 1995 to 2019.1
Results of the analysis showed 7.49% (n = 185,909) of children were exposed to acetaminophen during pregnancy. Also, crude absolute risks at 10 years for children not exposed vs children exposed to acetaminophen were 1.33% vs 1.53% for autism, 2.46% vs 2.87% for ADHD, and 0.70% vs 0.82% for intellectual disability.1
Additionally, in models without sibling control, ever-use vs no use of acetaminophen during pregnancy was associated with a slightly increased risk of autism (hazard ratio [HR], 1.05 [95%CI, 1.02-1.08]; risk difference [RD] at 10 years of age, 0.09% [95%CI, −0.01% to 0.20%]), ADHD (HR, 1.07 [95%CI, 1.05-1.10]; RD, 0.21% [95%CI, 0.08%-0.34%]), and intellectual disability (HR, 1.05 [95%CI, 1.00-1.10]; RD, 0.04%[95%CI, −0.04%to 0.12%]).1
Matched full sibling pairs were also analyzed to address unobserved confounding, according to the authors. Further results showed that sibling control analyses found no evidence that acetaminophen use during pregnancy was linked with autism (HR, 0.98 [95%CI, 0.93-1.04]; RD, 0.02%[95%CI, −0.14%to 0.18%]), ADHD (HR, 0.98 [95%CI, 0.94-1.02]; RD, −0.02%[95%CI, −0.21% to 0.15%]), or intellectual disability (HR, 1.01 [95%CI, 0.92-1.10]; RD, 0%[95%CI, −0.10% to 0.13%]).1
“This study’s findings may be welcome news for birthing people who use acetaminophen as a pain or fever management option since there are few safe alternatives for relief available,” said investigator Renee M. Gardner, PhD, Karolinska Institutet.5 “We hope that our results provide reassurance to expectant parents when faced with the sometimes fraught decision of whether to take these medications during pregnancy when suffering from pain or fever.”
References:
Study shows a healthy prenatal diet could be upstream obesity prevention strategy
December 26th 2024"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen